Jiahan Ke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiahan Ke has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jun Gu
Department of Dermatology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
3 shared publications - Xiaohan Qiu
Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
3 shared publications - Huafang Zhu
Shanghai Huangpu District Geriatric Care Hospital, Shanghai, China
2 shared publications - Huasu Zeng
Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
2 shared publications - Min Wang
Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
2 shared publications - Ben Hu
Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China
1 shared publication
Latest Publications
- Open Access
- 3 April 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (2) , 760-781
Global Co-occurrence Patterns of Cancer and Cardiovascular Disease: A Comprehensive Analysis Based on the Global Burden of Disease Study 2021
Introduction: Cardiovascular disease (CVD) and neoplasms are the two leading causes of death worldwide. Previous research has predominantly addressed these conditions separately or focused on specific regions. We aimed to characterize the global co-occurrence pattern of CVD and neoplasms from spatial and temporal perspectives and identify corresponding risk factors across different epidemiological contexts. Material and methods: Using GBD 2021 data, we extracted age-standardized disability-adjusted life years (DALYs) rates of CVD and neoplasms and modifiable risk factor exposure from 204 countries and territories (1990-2021). We identified four epidemiological patterns: low-burden, neoplasms-dominant, CVD-dominant, and dual-burden regions. We calculated population attributable fractions (PAF) and integrated machine learning with SHAP values to distinguish intervention priorities. Average annual percentage changes (AAPC) evaluated temporal trends. Results: Each pattern comprised 50-52 countries. Spatial distribution overlapped with socioeconomic development stages and risk factor exposure. Temporal analysis revealed widening global inequality: low-burden regions achieved 3-4% annual reductions while dual-burden regions experienced increasing burden, creating a 5.8 percentage point gap. High systolic blood pressure was the universal dominant CVD risk factor, accounting for 49.7% of global burden (49.2-52.4% across patterns). For neoplasms, smoking contributed 18.5% globally but varied dramatically by pattern (10.4-23.4%). Modifiable risk factors' specific combinations greatly influenced global disparities. Conclusions: The co-occurrence of CVD and neoplasms represents interconnected manifestations of different epidemiological transition stages, with concerning divergence between regions. Interventions targeting hypertension control and tobacco cessation, combined with pattern-specific strategies, can fundamentally reduce global disease burden.
- 3 April 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (2) , 760-781
Open AccessGlobal Co-occurrence Patterns of Cancer and Cardiovascular Disease: A Comprehensive Analysis Based on the Global Burden of Disease Study 2021
Introduction: Cardiovascular disease (CVD) and neoplasms are the two leading causes of death worldwide. Previous research has predominantly addressed these conditions separately or focused on specific regions. We aimed to characterize the global co-occurrence pattern of CVD and neoplasms from spatial and temporal perspectives and identify corresponding risk factors across different epidemiological contexts. Material and methods: Using GBD 2021 data, we extracted age-standardized disability-adjusted life years (DALYs) rates of CVD and neoplasms and modifiable risk factor exposure from 204 countries and territories (1990-2021). We identified four epidemiological patterns: low-burden, neoplasms-dominant, CVD-dominant, and dual-burden regions. We calculated population attributable fractions (PAF) and integrated machine learning with SHAP values to distinguish intervention priorities. Average annual percentage changes (AAPC) evaluated temporal trends. Results: Each pattern comprised 50-52 countries. Spatial distribution overlapped with socioeconomic development stages and risk factor exposure. Temporal analysis revealed widening global inequality: low-burden regions achieved 3-4% annual reductions while dual-burden regions experienced increasing burden, creating a 5.8 percentage point gap. High systolic blood pressure was the universal dominant CVD risk factor, accounting for 49.7% of global burden (49.2-52.4% across patterns). For neoplasms, smoking contributed 18.5% globally but varied dramatically by pattern (10.4-23.4%). Modifiable risk factors' specific combinations greatly influenced global disparities. Conclusions: The co-occurrence of CVD and neoplasms represents interconnected manifestations of different epidemiological transition stages, with concerning divergence between regions. Interventions targeting hypertension control and tobacco cessation, combined with pattern-specific strategies, can fundamentally reduce global disease burden.
- Open Access
- 22 September 2025
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 42 (6) , 495-505
Uric Acid-Lowering Therapy with Febuxostat in Patients with Chronic Heart Failure and Hyperuricemia: A Prospective and Observational Cohort Study
Hyperuricemia is associated with poor clinical outcomes in several cardiovascular diseases, including heart failure (HF). However, whether lowering serum uric acid (SUA) levels improves the prognosis of HF remains insufficiently studied. To evaluate whether urate-lowering therapy (ULT) with febuxostat confers clinical benefits in patients with HF and concomitant hyperuricemia. Prospective, observational cohort study. Patients with chronic HF and hyperuricemia were enrolled and assigned either to a febuxostat group or to a non-ULT group and were followed prospectively for 5 years. The primary endpoint was all-cause mortality or rehospitalization for HF. Among 2005 patients, those with higher SUA levels experienced more endpoint events. After propensity score matching, we found that febuxostat therapy significantly reduced the incidence of primary endpoints in patients with HFwith preserved ejection fraction (HFpEF) [p = 0.012; hazard ratios (HR), 0.744; 95% confidence intervals (CI), 0.589-0.939], but not in those with HF with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) (p = 0.234; HR, 0.894; 95% CI, 0.742-1.077). The benefits of febuxostat in HFpEF were most evident in patients within the highest tertiles of B-type natriuretic peptide (BNP) (p = 0.021; HR, 0.647; 95% CI, 0.436-0.960) and SUA (p = 0.025; HR, 0.651; 95% CI, 0.441-0.963). High SUA levels are associated with increased all-cause mortality and rehospitalization for HF. Febuxostat-mediated SUA reduction significantly improved clinical outcomes in patients with HFpEF, particularly those with elevated SUA and BNP levels.
- 22 September 2025
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 42 (6) , 495-505
Open AccessUric Acid-Lowering Therapy with Febuxostat in Patients with Chronic Heart Failure and Hyperuricemia: A Prospective and Observational Cohort Study
Hyperuricemia is associated with poor clinical outcomes in several cardiovascular diseases, including heart failure (HF). However, whether lowering serum uric acid (SUA) levels improves the prognosis of HF remains insufficiently studied. To evaluate whether urate-lowering therapy (ULT) with febuxostat confers clinical benefits in patients with HF and concomitant hyperuricemia. Prospective, observational cohort study. Patients with chronic HF and hyperuricemia were enrolled and assigned either to a febuxostat group or to a non-ULT group and were followed prospectively for 5 years. The primary endpoint was all-cause mortality or rehospitalization for HF. Among 2005 patients, those with higher SUA levels experienced more endpoint events. After propensity score matching, we found that febuxostat therapy significantly reduced the incidence of primary endpoints in patients with HFwith preserved ejection fraction (HFpEF) [p = 0.012; hazard ratios (HR), 0.744; 95% confidence intervals (CI), 0.589-0.939], but not in those with HF with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) (p = 0.234; HR, 0.894; 95% CI, 0.742-1.077). The benefits of febuxostat in HFpEF were most evident in patients within the highest tertiles of B-type natriuretic peptide (BNP) (p = 0.021; HR, 0.647; 95% CI, 0.436-0.960) and SUA (p = 0.025; HR, 0.651; 95% CI, 0.441-0.963). High SUA levels are associated with increased all-cause mortality and rehospitalization for HF. Febuxostat-mediated SUA reduction significantly improved clinical outcomes in patients with HFpEF, particularly those with elevated SUA and BNP levels.
- Open Access
- 1 January 2025
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1)
Preventive Effect of Shenfu Injection on Arrhythmia After Percutaneous Coronary Intervention in Patients With ST‐Segment Elevation Myocardial Infarction: A Prospective Randomized Controlled Trial
Background and Aims: Arrhythmias and major adverse cardiac events remain significant complications following ST‐segment elevation myocardial infarction (STEMI). Shenfu injection, a traditional Chinese medicine formulation, has shown cardioprotective effects in preclinical studies. This trial is aimed at investigating whether Shenfu injection as an adjunctive therapy to standard treatment could reduce arrhythmias and improve clinical outcomes in patients with STEMI undergoing percutaneous coronary intervention (PCI). Methods: A single‐center, prospective, randomized, controlled trial was conducted at Shanghai Ninth People′s Hospital among 245 patients with STEMI undergoing PCI. Participants were randomized to receive either standard therapy plus Shenfu injection (50 mL, administered intravenously twice daily for five consecutive days) ( n = 123) or standard therapy alone ( n = 122). The primary endpoint was the incidence of in‐hospital arrhythmias. Secondary endpoints included major adverse cardiac events (MACEs) during the 12‐month follow‐up period and cardiac magnetic resonance imaging parameters. Results: A total of 245 patients underwent randomization (123 assigned to Shenfu injection group and 122 assigned to control group). During hospitalization, patients assigned to Shenfu injection had a significantly lower incidence of arrhythmias compared with the control group (24.4% vs. 38.5%, p = 0.017), with the most pronounced effect on frequent ventricular premature contractions (7.3% vs. 15.5%, p = 0.042). After adjustment for key baseline covariates including age, coronary artery disease extent, myocardial injury markers (CK‐MB max and TNI max), left ventricular ejection fraction, B‐type natriuretic peptide, door‐to‐balloon time, hypertension, and diabetes mellitus, Shenfu injection remained independently associated with reduced risk of in‐hospital arrhythmias (adjusted OR 0.454, 95% CI: 0.249–0.827, p = 0.010). Cardiac magnetic resonance imaging performed in 174 patients revealed significantly smaller infarct size (16.1 ± 9.1 vs. 20.8 ± 13.1 g, p = 0.007) and lower incidence of microvascular obstruction (45.0% vs. 65.0%, p = 0.008) in the Shenfu group, with both parameters showing significant positive correlations with arrhythmia occurrence. During the 12‐month follow‐up, patients receiving Shenfu injection had a higher event‐free rate from MACEs compared with the control group (12‐month Kaplan‐Meier event‐free rate estimates, 84.6% vs. 73.0%, respectively; p = 0.028). Conclusions: Treatment with Shenfu injection as an adjunctive therapy to standard treatment in patients with STEMI undergoing PCI significantly reduced in‐hospital arrhythmias, infarct size, microvascular obstruction, and major adverse cardiac events during a 12‐month follow‐up period. The independent effect on arrhythmias after comprehensive statistical adjustment and the demonstrated correlation between reduced myocardial damage and arrhythmia prevention suggest the potential therapeutic value of Shenfu injection in improving both short‐term and long‐term outcomes in STEMI patients. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200066918
- 1 January 2025
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1)
Open AccessPreventive Effect of Shenfu Injection on Arrhythmia After Percutaneous Coronary Intervention in Patients With ST‐Segment Elevation Myocardial Infarction: A Prospective Randomized Controlled Trial
Background and Aims: Arrhythmias and major adverse cardiac events remain significant complications following ST‐segment elevation myocardial infarction (STEMI). Shenfu injection, a traditional Chinese medicine formulation, has shown cardioprotective effects in preclinical studies. This trial is aimed at investigating whether Shenfu injection as an adjunctive therapy to standard treatment could reduce arrhythmias and improve clinical outcomes in patients with STEMI undergoing percutaneous coronary intervention (PCI). Methods: A single‐center, prospective, randomized, controlled trial was conducted at Shanghai Ninth People′s Hospital among 245 patients with STEMI undergoing PCI. Participants were randomized to receive either standard therapy plus Shenfu injection (50 mL, administered intravenously twice daily for five consecutive days) ( n = 123) or standard therapy alone ( n = 122). The primary endpoint was the incidence of in‐hospital arrhythmias. Secondary endpoints included major adverse cardiac events (MACEs) during the 12‐month follow‐up period and cardiac magnetic resonance imaging parameters. Results: A total of 245 patients underwent randomization (123 assigned to Shenfu injection group and 122 assigned to control group). During hospitalization, patients assigned to Shenfu injection had a significantly lower incidence of arrhythmias compared with the control group (24.4% vs. 38.5%, p = 0.017), with the most pronounced effect on frequent ventricular premature contractions (7.3% vs. 15.5%, p = 0.042). After adjustment for key baseline covariates including age, coronary artery disease extent, myocardial injury markers (CK‐MB max and TNI max), left ventricular ejection fraction, B‐type natriuretic peptide, door‐to‐balloon time, hypertension, and diabetes mellitus, Shenfu injection remained independently associated with reduced risk of in‐hospital arrhythmias (adjusted OR 0.454, 95% CI: 0.249–0.827, p = 0.010). Cardiac magnetic resonance imaging performed in 174 patients revealed significantly smaller infarct size (16.1 ± 9.1 vs. 20.8 ± 13.1 g, p = 0.007) and lower incidence of microvascular obstruction (45.0% vs. 65.0%, p = 0.008) in the Shenfu group, with both parameters showing significant positive correlations with arrhythmia occurrence. During the 12‐month follow‐up, patients receiving Shenfu injection had a higher event‐free rate from MACEs compared with the control group (12‐month Kaplan‐Meier event‐free rate estimates, 84.6% vs. 73.0%, respectively; p = 0.028). Conclusions: Treatment with Shenfu injection as an adjunctive therapy to standard treatment in patients with STEMI undergoing PCI significantly reduced in‐hospital arrhythmias, infarct size, microvascular obstruction, and major adverse cardiac events during a 12‐month follow‐up period. The independent effect on arrhythmias after comprehensive statistical adjustment and the demonstrated correlation between reduced myocardial damage and arrhythmia prevention suggest the potential therapeutic value of Shenfu injection in improving both short‐term and long‐term outcomes in STEMI patients. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200066918